{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:36:21Z","timestamp":1780922181828,"version":"3.54.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018956","name":"NIHR Cambridge Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR203312"],"award-info":[{"award-number":["NIHR203312"]}],"id":[{"id":"10.13039\/501100018956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022011","name":"Cancer Research UK Cambridge Institute, University of Cambridge","doi-asserted-by":"publisher","award":["C9685\/A25117"],"award-info":[{"award-number":["C9685\/A25117"]}],"id":[{"id":"10.13039\/501100022011","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Advanced Accelerator Applications, a Novartis company, has provided funding and supply of kits for radiopharmaceutical preparation of [68Ga]NeoB.","award":["Advanced Accelerator Applications, a Novartis company, has provided funding and supply of kits for radiopharmaceutical preparation of [68Ga]NeoB."],"award-info":[{"award-number":["Advanced Accelerator Applications, a Novartis company, has provided funding and supply of kits for radiopharmaceutical preparation of [68Ga]NeoB."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Succinate dehydrogenase (SDH) deficient wild-type Gastrointestinal Stromal Tumours (wtGIST) are a rare GIST subtype with limited treatment options. Gallium-68 labelled Gastrin Releasing Peptide Receptor (GRPR) antagonist NeoB has shown promise in PET imaging for multiple primary malignancies. This investigation sought to assess the biodistribution of [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]NeoB via PET\/CT imaging in metastatic wtGIST patients and aimed to evaluate GRPR expression in lesions to determine the ligand\u2019s potential for patient selection in future therapeutic trials.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twelve patients with histologically confirmed metastatic wtGIST were enrolled. [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]NeoB PET\/CT imaging was conducted for lesion segmentation and analysis of uptake characteristics. 8 of 12 (66.7%) patients exhibited intense but heterogeneous [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]NeoB uptake in lesions, with variable tracer uptake both within and between lesions. Physiological uptake was highest in the pancreas, liver, and spleen. Four patients (33.3%) displayed minimal or no uptake in tumour lesions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The majority of wtGIST patients in this small cohort show lesions with intense [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]NeoB uptake. Heterogeneity of uptake indicates GRPR has highly variable inter- and intralesional expression. NeoB has potential for theranostic application in wtGIST, with limited effective standard of care treatments available. Ongoing trials are investigating the therapeutic use of [\n                      <jats:sup>177<\/jats:sup>\n                      Lu]NeoB in this setting.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13550-025-01299-3","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:58:01Z","timestamp":1761044281000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["In vivo gastrin releasing peptide receptor expression in SDH deficient wild-type gastrointestinal stromal tumours (GIST): potential for theranostic applications"],"prefix":"10.1186","volume":"15","author":[{"given":"David G. E.","family":"Hulse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fung","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gillett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Warnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"McLean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Wodtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdia","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eamonn R","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Giger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Bulusu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7452-4961","authenticated-orcid":false,"given":"Luigi","family":"Aloj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4058-3135","authenticated-orcid":false,"given":"Ruth T.","family":"Casey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"issue":"7","key":"1299_CR1","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1001\/jamaoncol.2016.0256","volume":"2","author":"SA Boikos","year":"2016","unstructured":"Boikos SA, Pappo AS, Killian JK, LaQuaglia MP, Weldon CB, George S, et al. Molecular subtypes of KIT\/PDGFRA Wild-Type Gastrointestinal stromal tumors: A report from the National institutes of health Gastrointestinal stromal tumor clinic. JAMA Oncol. 2016;2(7):922\u20138.","journal-title":"JAMA Oncol"},{"key":"1299_CR2","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1073\/pnas.1009199108","volume":"108","author":"KA Janeway","year":"2011","unstructured":"Janeway KA, Kim SY, Lodish M, Nose\u00b4 V, Rustin P, Gaal J, et al. Defects in succinate dehydrogenase in Gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci USA. 2011;108:314\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1299_CR3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s12020-014-0346-3","volume":"47","author":"A Sosipatros","year":"2014","unstructured":"Sosipatros A, Boikos Constantine A, Stratakis. The genetic landscape of Gastrointestinal stromal tumor lacking KIT and PDGFRA mutations. Endocrine. 2014;47:401\u20138.","journal-title":"Endocrine"},{"key":"1299_CR4","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.3390\/cancers14071832","volume":"14","author":"D van de Wal","year":"2022","unstructured":"van de Wal D, Elie M, Le Cesne A, Fumagalli E, den Hollander D, Jones RL, et al. Health-Related quality of life and side effects in Gastrointestinal stromal tumor (GIST) patients treated with tyrosine kinase inhibitors: A systematic review of the literature. Cancers. 2022;14:1832.","journal-title":"Cancers"},{"issue":"11","key":"1299_CR5","first-page":"1722","volume":"42","author":"C Van de Wiele","year":"2001","unstructured":"Van de Wiele C, Dumont F, Dierckx RA, Peers SH, Thornback JR, Slegers G, et al. Biodistribution and dosimetry of (99m)Tc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies. J Nucl Med. 2001;42(11):1722\u20137.","journal-title":"J Nucl Med"},{"issue":"11","key":"1299_CR6","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1038\/sj.bjc.6600957","volume":"2","author":"MK Waters","year":"2003","unstructured":"Waters MK, Cummings T-H, Jodrell H, et al. Increased gastrinreleasing peptide (GRP) receptor expression in tumour cells confers sensitivity to [Arg6,d-Trp7,9,NmePhe8]-substance P (6\u201311)-induced growth Inhibition. Br J Cancer. 2003;2(11):1808\u201316.","journal-title":"Br J Cancer"},{"key":"1299_CR7","doi-asserted-by":"crossref","unstructured":"Carroll M, Chakrabarti, McDonald B. 1999. Aberrant expression of gastrin releasing peptide and its receptor by well-differentiated colon cancers in humans. Am. J. Physiol. Gastrointest. Liver Physiol. 1999; 276(3):655\u2013665.","DOI":"10.1152\/ajpgi.1999.276.3.G655"},{"issue":"3","key":"1299_CR8","first-page":"327","volume":"17","author":"F Scopinaro","year":"2002","unstructured":"Scopinaro F, Varvarigou AD, Ussof W, De Vincentis G, Sourlingas TG, Evangelatos GP, et al. Technetium labeled bombesin-like peptide: preliminary report on breast cancer uptake in patients. Cancer Biother Radiopharm. 2002;17(3):327\u201335.","journal-title":"Cancer Biother Radiopharm"},{"issue":"4","key":"1299_CR9","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2967\/jnumed.115.168393","volume":"57","author":"R Minamimoto","year":"2016","unstructured":"Minamimoto R, Hancock S, Schneider B, Chin FT, Jamali M, Loening A, et al. Pilot comparison of 68Ga-RM2 PET and 68Ga-PSMA-11 PET in patients with biochemically recurrent prostate cancer. J Nucl Med. 2016;57(4):557\u201362.","journal-title":"J Nucl Med"},{"issue":"8","key":"1299_CR10","first-page":"302","volume":"31","author":"A Paulmichl","year":"2016","unstructured":"Paulmichl A, Summer D, Manzl C, Rangger C, Orlandi F, Niedermoser S, et al. Targeting Gastrointestinal stromal tumor with 68Ga-Labeled peptides: an in vitro study on Gastrointestinal stromal tumor-Cell lines. Cancer Biother Radiopharm. 2016;31(8):302\u201331.","journal-title":"Cancer Biother Radiopharm"},{"key":"1299_CR11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2967\/jnumed.116.176636","volume":"58","author":"S Dalm","year":"2017","unstructured":"Dalm S, Bakker I, de Blois E, Doeswijk G, Konijnenberg M, Orlandi F, et al. 68Ga\/177Lu-NeoBOMB1, a novel radiolabeled GRPR antagonist for theranostic use in oncology. J Nucl Med. 2017;58:293\u20139.","journal-title":"J Nucl Med"},{"key":"1299_CR12","unstructured":"Virgolini I, Decristoforo C. Jun. MITIGATE study report. EudraCT number 2016-002053-38. 2019. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-002053-38\/results"},{"issue":"11","key":"1299_CR13","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.3390\/biomedicines10112899","volume":"10","author":"L Gruber","year":"2022","unstructured":"Gruber L, Decristoforo C, Uprimny C, Hohenberger P, Schoenberg SO, Orlandi F, et al. Imaging properties and tumor targeting of 68Ga-NeoBOMB1, a Gastrin-Releasing peptide receptor antagonist, in GIST patients. Biomedicines. 2022;10(11):2899.","journal-title":"Biomedicines"},{"issue":"s1","key":"1299_CR14","first-page":"346","volume":"61","author":"L Djaileb","year":"2020","unstructured":"Djaileb L, Morgat C, Van de Veldt A, Virgolini I, Cortes F, Demange A, et al. Preliminary diagnostic performance of [68Ga]-NeoBOMB1 in patients with gastrinreleasing peptide receptor-positive breast, prostate, colorectal or lung tumors (NeoFIND). J Nucl Med. 2020;61(s1):346.","journal-title":"J Nucl Med"},{"key":"1299_CR15","unstructured":"Virgolini I, Wegener A, Cortes F. NeoFIND study report, 30 Mar 2020. Protocol number A005D-E01-201;EudraCT 2017-003432-37. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03724253"},{"key":"1299_CR16","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.2967\/jnumed.106.038091","volume":"48","author":"A Dimitrakopoulou-Strauss","year":"2007","unstructured":"Dimitrakopoulou-Strauss A, Hohenberger P, Haberkorn U, Macke HR, Eisenhut M, Strauss LG. 68Ga-labeled Bombesin studies in patients with Gastrointestinal stromal tumors: comparison with 18F-FDG. J Nucl Med. 2007;48:1245\u201350.","journal-title":"J Nucl Med"},{"issue":"4","key":"1299_CR17","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.cpet.2022.07.006","volume":"17","author":"H Duan","year":"2022","unstructured":"Duan H, Iagaru A. PET imaging using Gallium-68 (68Ga) RM2. PET Clin. 2022;17(4):621\u20139.","journal-title":"PET Clin"},{"issue":"10","key":"1299_CR18","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.7150\/thno.14958","volume":"19","author":"C Stoykow","year":"2016","unstructured":"Stoykow C, Erbes T, Maecke HR, Bulla S, Bartholom\u00e4 M, Mayer S, et al. Gastrin-releasing peptide receptor imaging in breast cancer using the receptor antagonist (68)Ga-RM2 and PET. Theranostics. 2016;19(10):1641\u201350.","journal-title":"Theranostics"},{"issue":"10","key":"1299_CR19","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.2967\/jnumed.108.052373","volume":"49","author":"I Ilias","year":"2008","unstructured":"Ilias I, Chen CC, Carrasquillo JA, Whatley M, Ling A, Lazurova I, et al. Comparison of 6\u201318F-fluorodopamine PET with 123I-metaiodoben-zylguanidine and 111In-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med. 2008;49(10):1613\u20139.","journal-title":"J Nucl Med"},{"key":"1299_CR20","doi-asserted-by":"publisher","first-page":"109821","DOI":"10.1016\/j.ejrad.2021.109821","volume":"141","author":"G Bottoni","year":"2021","unstructured":"Bottoni G, Piccardo A, Fiz F, Siri G, Matteucci F, Rocca A, et al. Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET\/CT and [18F]Fluorodeoxyglucose PET\/CT. Eur J Radiol. 2021;141:109821.","journal-title":"Eur J Radiol"},{"issue":"2","key":"1299_CR21","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1148\/rg.352140164","volume":"35","author":"MS Hofman","year":"2015","unstructured":"Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET\/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics. 2015;35(2):500\u201316.","journal-title":"Radiographics"},{"issue":"8","key":"1299_CR22","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.2967\/jnumed.114.137034","volume":"55","author":"A van Berkel","year":"2014","unstructured":"van Berkel A, Rao JU, Kusters B, Demir T, Visser E, Mensenkamp AR, et al. Correlation between in vivo 18F-FDG PET and immunohistochemical markers of glucose uptake and metabolism in pheochromocytoma and paraganglioma. J Nucl Med. 2014;55(8):1253\u20139.","journal-title":"J Nucl Med"},{"key":"1299_CR23","doi-asserted-by":"crossref","unstructured":"Berndsen M, Puls F, Thornell A, Arvidsson Y, Muth A, Lindskog S, Elias E. 2024. Gastrin-Releasing Peptide Receptor Expression in Gastrointestinal Stromal Tumours. ESMO Gastrointestinal Oncology 6 (December).","DOI":"10.1016\/j.esmogo.2024.100105"},{"key":"1299_CR24","doi-asserted-by":"crossref","unstructured":"Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 991;21(1):109\u201322.","DOI":"10.1016\/0360-3016(91)90171-Y"},{"key":"1299_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/1748-717X-8-247","volume":"8","author":"S Bresciani","year":"2013","unstructured":"Bresciani S, Garibaldi E, Cattari G, Maggio A, Di Dia A, Delmastro E, et al. Dose to organs at risk in the upper abdomen in patients treated with extended fields by helical tomotherapy: a dosimetric and clinical preliminary study. Radiat Oncol. 2013;8:247.","journal-title":"Radiat Oncol"},{"issue":"12","key":"1299_CR26","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.2967\/jnumed.119.238808","volume":"61","author":"LD Leonhard Gruber","year":"2020","unstructured":"Leonhard Gruber LD, Jim\u00e9nez-Franco C, Decristoforo C, Uprimny G, Glatting P, Hohenberger SO, Schoenberg W, Reindl F, Orlandi M, Mariani W, Jaschke I, Virgolini. MITIGATE-NeoBOMB1, a phase i\/iia study to evaluate safety, pharmacokinetics, and preliminary imaging of 68Ga-NeoBOMB1, a Gastrin-Releasing peptide receptor antagonist, in GIST patients. Journal Nuclear Medicine Dec. 2020;61(12):1749\u201355. https:\/\/doi.org\/10.2967\/jnumed.119.238808.","journal-title":"Journal Nuclear Medicine Dec"},{"issue":"13","key":"1299_CR27","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.1007\/s00259-022-05926-2","volume":"49","author":"EAM Ruigrok","year":"2022","unstructured":"Ruigrok EAM, Verhoeven M, Konijnenberg MW, de Blois E, de Ridder CMA, Stuurman DC, Bertarione L, Rolfo K, de Jong M, Dalm SU. Safety of [177Lu]Lu-NeoB treatment: a preclinical study characterizing absorbed dose and acute, early, and late organ toxicity. Eur J Nucl Med Mol Imaging. 2022;49(13):4440\u201351. Epub 2022 Aug 11. PMID: 35951084; PMCID: PMC9605926.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1299_CR28","doi-asserted-by":"publisher","unstructured":"Kurth J, Krause BJ, Schwarzenb\u00f6ck SM, Bergner C, Hakenberg OW, Heuschkel M. First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [177Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2020;47(1):123\u2013135. https:\/\/doi.org\/10.1007\/s00259-019-04504-3. Epub 2019 Sep 3. PMID: 31482426.","DOI":"10.1007\/s00259-019-04504-3"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01299-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-025-01299-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01299-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:05:43Z","timestamp":1761087943000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-025-01299-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1299"],"URL":"https:\/\/doi.org\/10.1186\/s13550-025-01299-3","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"25 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the East of England South Cambridge Research Ethics Committee (REC ID 14\/EE\/1059). All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Figs.\u00a0\n                      \n                      ,\n                      \n                      and\n                      \n                      .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have not competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"132"}}